Premium
Aspirin reduces the incidence of colonic carcinoma in the dimethylhydrazine rat animal model
Author(s) -
Davis A. E.,
Patterson F.
Publication year - 1994
Publication title -
australian and new zealand journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 0004-8291
DOI - 10.1111/j.1445-5994.1994.tb02176.x
Subject(s) - aspirin , medicine , dimethylhydrazine , colorectal cancer , incidence (geometry) , colonic cancer , gastroenterology , epidemiology , colonic carcinoma , 1,2 dimethylhydrazine , carcinoma , cancer , animal model , physics , optics
Background : Epidemiological studies in humans suggest that regular use of non‐steroidal anti‐inflammatory drugs (NSAIDs) especially aspirin significantly decreases the risk of developing colorectal cancer. Aims : The purpose of this study was to investigate the effect of aspirin on colonic carcinogenesis using the dimethylhydrazine (DMH) colonic cancer model in rats. Methods : Groups of animals were given daily doses of aspirin either 0, 5, 30 or 60 mg/kg for 18 weeks. Half of each group also received 18 × 30 mg/kg/wk injections of DMH. Results : Aspirin at doses of 5, 30 or 60 mg/kg/dy had a progressive effect on the reduction of tumour numbers and the percentage of tumours greater or equal to 5 mm in diameter. Aspirin at doses of 30 and 60 mg/kg/dy significantly reduced tumour incidence. Conclusion : These findings support the epidemiological studies in humans. The rat DMH model would appear to be suitable for investigating the mechanism of action of aspirin in reducing colonic tumour formation.